ASCO 2021 Breast Cancer - Physician's Weekly


ASCO 2021 Breast Cancer

T-DXd Combinations in HER2-positive Metastatic Breast Cancer

The DESTINY-Breast07 trial will test trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer, as a phase 1b/2, open-label, multicenter, dose-finding and dose-expansion...

T-DXd Response on Brain Mets HER2+ Breast Cancer

Results from the phase 2 clinical trial DESTINY-Breast01 showed that the investigational human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) has just as durable...

Financial Toxicity in Women with Breast Cancer

Patients with breast cancer prioritized affordability or maintaining functional independence when making treatment decisions. Because of this variability, preference evaluation during treatment decision-making could optimize...

The Mutations That Cause Highest Risk for Breast Cancer

Germline DNA samples from African American women from 10 U.S. studies were tested for mutations in 20 established breast cancer predisposition genes using a QIAseq multiplex amplicon panel as part of the Cancer Risk Estimates...



For latest news and updates
Email-id is invalid